Clinical effect of two different regimens in treatment of acute lymphoblastic leukemia children with bone marrow recurrence
ZHAO Bei-Bei, CHEN Xiao-Juan, GUO Ye, YANG Wen-Yu, ZOU Yao, CHEN Yu-Mei, ZHANG Li, RUAN Min, LIU Xiao-Ming, LIU Fang, LIU Tian-Feng, QI Ben-Quan, ZHU Xiao-Fan
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology&Blood Diseases Hospital, Chinese Academy of Medical Sciences&Peking Union Medical College, Tianjin 300020, China
Abstract Objective To study the short-term effect of two different re-induction regimens in the treatment of acute lymphoblastic leukemia (ALL) children with bone marrow recurrence. Methods A retrospective analysis was performed for 57 ALL children with bone marrow recurrence. According to their treatment regimen, they were divided into two groups: VMDP (vincristine + mitoxantrone + dexamethasone + PEG-asparaginase; n=42) and VIDP (vincristine + idarubicin + dexamethasone + PEG-asparaginase; n=15). The two groups were compared in terms of complete response rate and incidence rate of adverse reactions. Results There was no significant difference in complete response rate between the VMDP and VIDP groups (74% vs 73%, P > 0.05). All children experienced grade ≥3 hematological adverse events. The VMDP group had a significantly lower chemotherapy-related mortality rate than the VIDP group (P < 0.05). There was no significant difference in the incidence rate of infection between the two groups (P > 0.05). Conclusions For ALL children with bone marrow recurrence, both re-induction regimens can achieve a relatively high complete response rate, and VMDP regimen has a lower chemotherapy-related mortality rate and can thus be used as an option for re-induction in ALL children with bone marrow recurrence.
ZHAO Bei-Bei,CHEN Xiao-Juan,GUO Ye et al. Clinical effect of two different regimens in treatment of acute lymphoblastic leukemia children with bone marrow recurrence[J]. CJCP, 2020, 22(4): 346-349.
ZHAO Bei-Bei,CHEN Xiao-Juan,GUO Ye et al. Clinical effect of two different regimens in treatment of acute lymphoblastic leukemia children with bone marrow recurrence[J]. CJCP, 2020, 22(4): 346-349.
Zheng R, Peng X, Zeng H, et al. Incidence, mortality and survival of childhood cancer in China during 2000-2010 period:a population-based study[J]. Cancer Lett, 2015, 363(2):176-180.
Singh N, Frey NV, Grupp SA, et al. CAR T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia[J]. Curr Treat Options Oncol, 2016, 17(6):28.
[4]
Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005:a report from the Children's Oncology Group[J]. J Clin Oncol, 2012, 30(14):1663-1669.
Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALI-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia[J]. Leukemia, 2010, 24(2):345-354.
[7]
Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy:results of trial ALL-REZ BFM 90[J]. J Clin Oncol, 2010, 28(14):2339-2347.
Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3):an open-label randomised trial[J]. Lancet, 2010, 376(9757):2009-2017.
National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.4.0[DB/OL]. (2010-06-14)[2019-08-01]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
[12]
Ghorashian S, Kramer AM, Onuoha S, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR[J]. Nat Med, 2019, 25(9):1408-1414.
[13]
Camuset M, Grain A, Lorton F, et al. Use of blinatumomab in children acute lymphoblastic leukemia in the Grand Ouest interregion:a chance for all[J]. Bull Cancer, 2019, 106(3):206-215.
[14]
Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclphosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia[J]. Br J Haematol, 2009, 147(3):371-378.
[15]
Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL):a report from the therapeutic advances in childhood leukemia (TACL) consortium[J]. Pediatr Blood Cancer, 2010, 55(2):254-259.
[16]
Cooper TM, Razzouk BI, Gerbing R, et al. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523):a report from the Children's Oncology Group[J]. Pediatr Blood Cancer, 2013, 60(7):1141-1147.
[17]
Sun W, Orgel E, Malvar J, et al. Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2016, 63(11):1943-1948.